Inhibition of TRAF6‐dependent signaling using a UBE2N inhibitor can suppress leukemic HSPCs, underscoring the therapeutic potential of targeting innate immune pathways in AML, further highlighting the critical role of TLR4 signaling in maintaining the inflammatory microenvironment that promotes leukemic progression [33]. Here, UBE2N is linked to acute myeloid leukemia.